Lyell Immunopharma (LYEL) Competitors $0.43 -0.01 (-1.23%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.32%) As of 04/17/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYEL vs. OPT, COGT, BCAX, IMNM, VALN, MRVI, DNTH, ORGO, GHRS, and ALMSShould you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Opthea (OPT), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Immunome (IMNM), Valneva (VALN), Maravai LifeSciences (MRVI), Dianthus Therapeutics (DNTH), Organogenesis (ORGO), GH Research (GHRS), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Lyell Immunopharma vs. Opthea Cogent Biosciences Bicara Therapeutics Immunome Valneva Maravai LifeSciences Dianthus Therapeutics Organogenesis GH Research Alumis Opthea (NASDAQ:OPT) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends. Which has more risk & volatility, OPT or LYEL? Opthea has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. Which has stronger earnings & valuation, OPT or LYEL? Opthea has higher revenue and earnings than Lyell Immunopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$87.67K5,986.77-$220.24MN/AN/ALyell Immunopharma$61K2,098.55-$234.63M-$1.31-0.33 Do analysts recommend OPT or LYEL? Opthea presently has a consensus price target of $1.33, suggesting a potential downside of 60.90%. Lyell Immunopharma has a consensus price target of $1.00, suggesting a potential upside of 130.63%. Given Lyell Immunopharma's higher possible upside, analysts clearly believe Lyell Immunopharma is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the MarketBeat Community favor OPT or LYEL? Opthea received 5 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 48.72% of users gave Opthea an outperform vote while only 45.16% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformOptheaOutperform Votes1948.72% Underperform Votes2051.28% Lyell ImmunopharmaOutperform Votes1445.16% Underperform Votes1754.84% Do insiders and institutionals hold more shares of OPT or LYEL? 56.0% of Opthea shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is OPT or LYEL more profitable? Opthea has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Opthea's return on equity of 0.00% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Lyell Immunopharma -323,792.09%-34.64%-30.02% Does the media favor OPT or LYEL? In the previous week, Lyell Immunopharma had 2 more articles in the media than Opthea. MarketBeat recorded 4 mentions for Lyell Immunopharma and 2 mentions for Opthea. Lyell Immunopharma's average media sentiment score of 0.22 beat Opthea's score of -0.08 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOpthea beats Lyell Immunopharma on 11 of the 16 factors compared between the two stocks. Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYEL vs. The Competition Export to ExcelMetricLyell ImmunopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.01M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.556.8921.8017.77Price / Sales2,098.55231.02379.9097.68Price / CashN/A65.6738.2634.64Price / Book0.175.916.443.98Net Income-$234.63M$142.72M$3.21B$247.52M7 Day Performance-1.12%4.35%2.84%1.82%1 Month Performance-10.36%-12.79%-8.65%-6.98%1 Year Performance-81.39%-9.70%11.38%1.49% Lyell Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYELLyell Immunopharma3.1963 of 5 stars$0.43-1.2%$1.00+130.6%-81.8%$128.01M$61,000.00-0.55270Analyst ForecastGap DownOPTOpthea0.7611 of 5 stars$3.41+7.2%$1.33-60.9%-0.3%$524.84M$87,666.000.008Gap UpCOGTCogent Biosciences2.4597 of 5 stars$4.58-4.0%$14.43+215.0%-33.1%$521.43MN/A-1.8580Positive NewsHigh Trading VolumeBCAXBicara TherapeuticsN/A$9.51-10.0%$36.50+283.8%N/A$518.51MN/A0.0032Analyst ForecastNews CoverageGap DownIMNMImmunome2.5288 of 5 stars$5.88-0.8%$25.14+327.6%-54.5%$511.27M$9.04M-0.7340Positive NewsVALNValneva1.8012 of 5 stars$6.24+4.3%$16.00+156.4%-12.4%$507.07M$169.58M-48.00700Analyst ForecastGap UpMRVIMaravai LifeSciences4.3669 of 5 stars$1.99+2.6%$7.31+267.1%-77.1%$506.13M$259.19M-1.21610Options VolumeDNTHDianthus Therapeutics2.0964 of 5 stars$15.61-3.2%$54.33+248.1%-16.5%$501.47M$6.24M-6.2480Positive NewsORGOOrganogenesis3.8643 of 5 stars$3.89+0.5%$5.50+41.4%+51.3%$493.36M$482.04M-64.83950GHRSGH Research2.4238 of 5 stars$9.32-7.6%$30.86+231.1%-17.2%$484.90MN/A-11.8010Gap DownHigh Trading VolumeALMSAlumis2.4788 of 5 stars$10.07+0.2%$26.00+158.2%N/A$475.53MN/A0.00N/APositive NewsHigh Trading Volume Related Companies and Tools Related Companies OPT Alternatives COGT Alternatives BCAX Alternatives IMNM Alternatives VALN Alternatives MRVI Alternatives DNTH Alternatives ORGO Alternatives GHRS Alternatives ALMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYEL) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LYEL Stock Free LYEL Stock Alerts